Autonomix Medical, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in precision nerve-targeted treatments, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. Brad Hauser, President and CEO, presented the company's top five reasons why investors and industry professionals should monitor Autonomix in 2025. The presentation is now available for viewing on the company's website and through a direct webcast link.
Autonomix Medical (NASDAQ: AMIX), un'azienda di dispositivi medici specializzata in trattamenti precisi mirati ai nervi, ha partecipato alla Conferenza Virtuale per Investitori 'Top 5 per il '25' On-Demand. Brad Hauser, Presidente e CEO, ha presentato i cinque motivi principali per cui investitori e professionisti del settore dovrebbero tenere d'occhio Autonomix nel 2025. La presentazione è ora disponibile per la visione sul sito web dell'azienda e tramite un link di webcast diretto.
Autonomix Medical (NASDAQ: AMIX), una empresa de dispositivos médicos especializada en tratamientos de precisión dirigidos a los nervios, ha participado en la Conferencia Virtual para Inversores 'Top 5 para el '25' On-Demand. Brad Hauser, Presidente y CEO, presentó las cinco principales razones por las que los inversores y profesionales de la industria deberían seguir a Autonomix en 2025. La presentación ya está disponible para su visualización en el sitio web de la empresa y a través de un enlace de webcast directo.
Autonomix Medical (NASDAQ: AMIX), 정밀 신경 표적 치료를 전문으로 하는 의료 기기 회사가 '25년을 위한 상위 5개' 가상 투자자 회의에 참여했습니다. Brad Hauser 사장 겸 CEO는 투자자와 업계 전문가들이 2025년 Autonomix를 주목해야 하는 다섯 가지 주요 이유를 발표했습니다. 발표 내용은 현재 회사 웹사이트와 직접 웹캐스트 링크를 통해 시청할 수 있습니다.
Autonomix Medical (NASDAQ: AMIX), une entreprise de dispositifs médicaux spécialisée dans des traitements précis ciblant les nerfs, a participé à la Conférence Virtuelle des Investisseurs 'Top 5 pour '25' à la demande. Brad Hauser, Président et CEO, a présenté les cinq principales raisons pour lesquelles les investisseurs et les professionnels de l'industrie devraient suivre Autonomix en 2025. La présentation est désormais disponible à la visualisation sur le site web de l'entreprise et via un lien de webdiffusion directe.
Autonomix Medical (NASDAQ: AMIX), ein Medizintechnikunternehmen, das sich auf präzise, nervenspezifische Behandlungen spezialisiert hat, hat an der virtuellen Investorenkonferenz 'Top 5 für '25' On-Demand teilgenommen. Brad Hauser, Präsident und CEO, präsentierte die fünf Hauptgründe, warum Investoren und Fachleute der Branche Autonomix im Jahr 2025 im Auge behalten sollten. Die Präsentation ist jetzt auf der Website des Unternehmens und über einen direkten Webcast-Link verfügbar.
- None.
- None.
On-demand video webcast now available here
THE WOODLANDS, TX, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it participated in the Virtual Investor “Top 5 for ‘25” On-Demand Conference.
As part of the event, Brad Hauser, President and Chief Executive Officer of Autonomix, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Autonomix in 2025.
The on-demand video webcast is now accessible for viewing here and on the Events page in the Investors section of the Company’s website (autonomix.com).
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024 and the Offering Prospectus filed with the SEC on November 25, 2024, and in other filings made by us from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
What did Autonomix Medical (AMIX) present at the Virtual Investor Top 5 for '25 Conference?
Where can investors watch Autonomix Medical's (AMIX) Top 5 for '25 presentation?
What is Autonomix Medical's (AMIX) main business focus?
When did Autonomix Medical (AMIX) participate in the Virtual Investor Conference?
